OSAKA -- Fujisawa Pharmaceutical Co. said Friday it will reorganize its European subsidiaries by Jan. 1, 2002, in an effort to boost sales in Europe.
The reorganization will coincide with the launch in Europe next year of the company's mainstay product, a drug for atopic dermatitis, the firm said. It aims to increase sales primarily in Germany, Austria and Switzerland.
Fujisawa Europe GmbH, a European holding company, and its subsidiary were merged into Fujisawa GmbH on Jan. 1 as the first step in the reorganization.
The company also plans to make Klinge Pharma GmbH, a Munich-based pharmaceutical firm in which it holds a minority stake, a wholly owned subsidiary by Jan. 1 next year, it said.